Integrin alpha 5 beta 1

Integrin alpha 5 beta 1 Molekülinformation

Englischer Name	Integrin alpha-5/beta-1	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	4	Target-Alias	Integrin alpha5beta1
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Integrin alpha-5/beta-1
Target-Alias	Integrin alpha5beta1
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	4
Höchste Forschungs- und Entwicklungsphase	Approved

Integrin alpha 5 beta 1 Produktliste

Attribut
Protein (3)
Produktbibliothek
Online (3)
Spezies
Human (2)Cynomolgus (1)
Etikett
His Tag (2)His Tag & Avi Tag (1)
Marker
Unconjugated (2)Biotin-labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT IT1-H52W5	Human	HEK293	Human Integrin alpha 5 beta 1 (ITGA5&ITGB1) Heterodimer Protein, His Tag&Tag Free, low endotoxin	In den Warenkorb legen
IT1-H82Wa	Human	HEK293	Biotinylated Human Integrin alpha 5 beta 1 (ITGA5&ITGB1) Heterodimer Protein, His,Avitag™&Tag Free	In den Warenkorb legen
IT1-C52W7	Cynomolgus	HEK293	Cynomolgus Integrin alpha 5 beta 1 (ITGA5&ITGB1) Heterodimer Protein, His Tag&Tag Free (MALS verified)	In den Warenkorb legen

Gesamtmenge3

Integrin alpha 5 beta 1 Molekülhintergrund

Integrin alpha 5 beta 1 / Integrin α5β1, which is a major cellular receptor for the extracellular matrix protein fibronectin and plays a fundamental role during mammalian development., is composed of α5 (ITGA5/CD49e) and β1 (ITGB1/CD29) subunits. Integrins are adhesion receptors that transmit bidirectional signals across the plasma membrane. The Integrin alpha 5 beta 1 and its primary extracellular matrix ligand fibronectin (Fn) are of great biological importance.

Integrin alpha 5 beta 1 Molekülalias

Integrin alpha 5 beta 1,ITGA5&ITGB1

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Risuteganib	ALG-1001; AM011; AM-011(Allegro Ophthalmics)	Phase 1 Clinical	Allegro Ophthalmics Llc	Diabetic macular oedema; Diabetic Retinopathy; Geographic Atrophy; Macular Degeneration	Details
Pegylated recombinant human endostatin (Tsinghua University)	M-2ES; CRB-0401	Phase 1 Clinical	Beijing Proji Pharmaceutical Technology Co Ltd, Beijing Protgen Biotechnology Development Co Ltd, Tsinghua University	Carcinoma, Non-Small-Cell Lung; Neoplasms; Pancreatic Neoplasms; Solid tumours	Details
VAX-014	VAX-014	Phase 1 Clinical	Vaxiion Therapeutics Llc	Solid tumours	Details
Integrin α5β1 therapy (Eli Lilly and Company)		Phase 1 Clinical	Eli Lilly And Company	Cardiovascular Diseases	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Recombinant human endostatin (Simcere)	YH-16	Approved	Jiangsu Simcere Pharmaceutical Co Ltd	Endostar, 恩度, Endu	Mainland China	Carcinoma, Non-Small-Cell Lung	Shandong Xiansheng Zaiming Biopharmaceutical Co Ltd	2005-09-12	Ascites; Brain metastases; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Nasopharyngeal Carcinoma; Osteosarcoma; Pleural Effusion, Malignant	Details